RIGEL PHARMACEUTICALS 8-K: Financial Condition & Other Events Update

TL;DR

**Rigel just dropped an 8-K on financial results and other events, signaling important updates for investors.**

AI Summary

Rigel Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to report on 'Results of Operations and Financial Condition' and 'Other Events.' This filing indicates that the company is providing an update on its financial performance and other significant developments. For investors, this matters because it offers a timely glimpse into the company's current financial health and any recent material events that could influence its stock price, allowing them to assess potential risks or opportunities.

Why It Matters

This filing provides a crucial, immediate update on Rigel's financial health and any significant recent events, which can directly impact investor sentiment and stock valuation.

Risk Assessment

Risk Level: medium — The filing itself doesn't detail the financial results or other events, so the actual impact and risk are unknown until the full content is reviewed.

Analyst Insight

A smart investor would immediately seek out the full text of this 8-K filing to understand the specific financial results and 'Other Events' disclosed, as these details are critical for assessing Rigel's current valuation and future prospects.

Key Numbers

• 20240108 — Filing Date (The date the 8-K was filed, indicating the timeliness of the information.)
• 000-29889 — SEC File Number (Unique identifier for Rigel's filings with the SEC.)
• 94-3248524 — IRS Employer Identification No. (Rigel Pharmaceuticals' tax identification number.)
• 650-624-1100 — Business Phone Number (Contact information for Rigel Pharmaceuticals.)
• 14 — Public Document Count (Number of documents included in this specific filing.)

Key Players & Entities

• RIGEL PHARMACEUTICALS INC (company) — the registrant filing the 8-K
• 0001034842 (company) — Central Index Key (CIK) for Rigel Pharmaceuticals
• January 8, 2024 (date) — date of earliest event reported and filing date
• Delaware (company) — state of incorporation for Rigel Pharmaceuticals
• RIGL (company) — trading symbol for Rigel Pharmaceuticals
• The Nasdaq Stock Market LLC (company) — exchange where Rigel's common stock is registered
• $0.001 (dollar_amount) — par value per share of common stock

Forward-Looking Statements

• Rigel Pharmaceuticals will provide detailed financial figures for its 'Results of Operations and Financial Condition' in the full filing. (RIGEL PHARMACEUTICALS INC) — high confidence, target: 2024-01-08
• The 'Other Events' section will disclose a material non-financial development impacting the company. (RIGEL PHARMACEUTICALS INC) — medium confidence, target: 2024-01-08

FAQ

Key Financial Figures

• $0.001 — h Registered Common Stock, par value $0.001 per share RIGL The Nasdaq Stock Mar

Filing Documents

• tm242328d1_8k.htm (8-K) — 26KB
• tm242328d1_ex99-1.htm (EX-99.1) — 55KB
• tm242328d1_ex99-1img001.jpg (GRAPHIC) — 4KB
• 0001104659-24-002085.txt ( ) — 269KB
• rigl-20240108.xsd (EX-101.SCH) — 3KB
• rigl-20240108_lab.xml (EX-101.LAB) — 33KB
• rigl-20240108_pre.xml (EX-101.PRE) — 22KB
• tm242328d1_8k_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. In connection with the press release described in Item 8.01 below, on January 8, 2024, Rigel Pharmaceuticals, Inc. ("Rigel") provided, on a preliminary and unaudited basis, certain estimated financial results for its fourth quarter and fiscal year ended December 31, 2023. The preliminary estimates are based on currently available information and do not present all necessary information for a complete understanding of Rigel's financial condition as of December 31, 2023 or Rigel's results of operations for the fourth quarter or year ended December 31, 2023.

01. Other Events

Item 8.01. Other Events. On January 8, 2024, Rigel issued a press release titled "Rigel Pharmaceuticals Provides Business Update." A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release, dated January 8, 2024, titled "Rigel Pharmaceuticals Provides Business Update" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 8, 2024 RIGEL PHARMACEUTICALS, INC. By: /s/ Ray Furey, J.D. Ray Furey, J.D. Executive Vice President, General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR